Augmentiqs Announces a Rental and Leasing Telepathology Service to Assist Pathology Labs with Implementing Remote Consultations Due to COVID-19

Short term rental and leasing model will allow pathology labs to immediately implement digital pathology applications within the current budget cycle

Real-time telepathology and digital pathology provider Augmentiqs announced the introduction of a new payment model for telepathology, allowing pathology labs to immediately integrate the Augmentiqs’ solution for real-time telepathology.  The main goals of this rental and leasing pricing model are to reduce the internal challenges of labs in integrating new technologies, a process that generally requires prior approval in the annual budget.  This telepathology as a service model should help labs maintain, and even improve performance during a time when travel restrictions being placed have the potential to negatively effect lab operations.

The simple rental agreement for the Augmentiqs imaging system and software is $750 per month, allowing a low-risk and immediate solution that combines high resolution microscope imaging with real-time communications.

Telepathology as a Service

Augmentiqs will allow labs to rent the Augmentiqs system on a short term basis with no commitment to purchase, or to spread out payments for a full purchase until the next fiscal year.  $750 per month for a Plug & Play solution that operates directly from the existing microscope and PC.

Labs interested in renting the system with Augmented Reality and pathology informatics capabilities may do so for an extra $200 per month/per add-on.

*While supplies last. Contact Augmentiqs for all terms and conditions.

Contact Augmentiqs

5 + 15 =

Regulatory Aspects of Remote Telepathology for Clinical and Toxicologic Pathology

Statement by Dr. Bob Maronpot Regarding Augmentiqs, GLP and Regulatory Aspects of Online Peer Review

bob-maronpot-toxpath-telepathology

Robert R. Maronpot, DVM, MS, MPH, DACVP, DABT,

“I am a scientific advisor for San-Ei Gen FFI, Inc of Japan and represent the Gardenia Blue Interest Group funded for toxicology studies by the Japanese government. Dr. Abraham Nyska has done all of our peer reviews and is scheduled for future peer reviews.
All have been done using the Augmentiqs system that allows multiple scientists in different parts of the world to observe the slides and discuss the pathology during the peer review. In other words, the Augmentiqs allows for active dialogue involving all stakeholders.
Following the dialogue, a formal peer review report is issued and this report is totally GLP-compliant. Further, it is the same peer review documentation that would occur even if there were no Augmentiqs teleconversation discussion of the peer review findings. So, there should be no concern about using the Augmentiqs with regard to regulatory authorities. In fact, using the system is an added benefit in allowing important dialogue among all interests parties.
As far as I am concerned, there is no compelling need for any variation as the dialogue is basically a telephone conversation with the added ability to see the slides in real time.”
“CMS will allow laboratories to utilize temporary testing sites for remote review and reporting of laboratory data/slides/images as long as specific criteria are met.”

clia-telepathology-letterAs of March 26, CMS has granted a waiver for labs to conduct remote signout from non-CLIA certified locations. 

Click here to download a paper from Charles River Laboratories concerning the use of Augmentiqs for GLP studies.

Click here to download the full COVID-19 CLIA exemption letter from CMS.

Click here to download a case study from Thomas Jefferson University concerning use of Augmentiqs for interoperative consultations (frozen sections).

The Coronavirus has resulted in severe international and intra-national travel restrictions. Remote telepathology rentals can assist labs that are now cash-strapped or operating on annual budgets

“Almost all laboratories operate on annual budgets, with new pieces of capital equipment oftentimes requiring many months until being cleared for purchase. While necessary for any business, instances such as the Coronavirus pandemic, with its ability to severely hamper travel can potentially have a devastating effect on the pathology lab,” outlines Gabe Siegel, CEO and co-founder of Augmentiqs. “By allowing labs to rent out equipment and software in a single solution, we can now allow pathology labs to leverage their ongoing budgets to integrate critical remote telepathology capabilities. The typical high-throughput lab can now take advantage of an intuitive, plug & play, and real-time telepathology solution in an immediate and budget-conscious fashion.”

 

About Augmentiqs

Augmentiqs is a microscope-centric approach to digital pathology, providing pathologists a cost-efficient and low-data method for realizing clinical and workflow enhancements. By connecting the analog microscope to the computer, Augmentiqs maintains the advantages of the microscope for workflow and primary diagnosis, while improving efficiency with the introduction of pathology software applications directly from the microscope.

By functioning as a platform for real-time software deployment within the microscope, Augmentiqs allows pathologists immediate access to imaging, analytical software, telepathology, LIMS integration and other digital pathology applications.

For more information about Augmentiqs, please visit www.augmentiqs.com or contact sales@augmentiqs.com.

    Telepathology as a Service & the Cancelled Peer Review

 The decision by Augmentiqs to enable labs to utilize a service-based pricing model for its telepathology equipment stems from the first (almost) cancelled peer review due to travel restrictions put in place in response to the Coronavirus pandemic. The sponsor, a developer of a novel treatment for cancer, had a peer review scheduled at Charles River Laboratories. The pharmaceutical company’s hired peer review pathologist was scheduled to fly from to the CRL lab, but due to the closure of the international route and likelihood of mandatory quarantine upon return, decided to forego the trip and cancel the peer review.

Yet as the peer review plays a pivotal role in the regulatory process, it was recommended to ship the slides to a different Charles River lab in the U.S. that is already actively using the Augmentiqs telepathology system for peer review. From that lab, images of the slides will be shared in real-time with the peer review pathologist, who will communicate in real-time with the Charles River study pathologist.

This event clearly shows the value that real-time telepathology can bring to pathology labs, both toxicologic and clinical. While in this instance Charles River had already installed Augmentiqs at multiple locations, many labs that will soon find themselves in a situation where real-time remote collaboration will be required, but this implementation will be hampered due to budget and supply chain.